레드 바이오테크놀러지 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Red Biotechnology Market Summary

The global red biotechnology market size was estimated at USD 546.59 billion in 2024, and is projected to reach USD 997.74 billion by 2030, growing at a CAGR of 10.5% from 2025 to 2030. The increasing demand for personalized medicine, high investment in the R&D of biotechnology products, and advances in genetic research are shaping the field.

Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in fighting diseases. It is a subset of modern technology used in the field of medicine. It finds application in the pharmaceutical industry and the medical sector, as it helps alleviate human suffering and improves the quality of life. The increasing usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.

The market is expected to witness lucrative growth during the forecast period. It has made significant advancements in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS, including azidothymidine, which has helped manage AIDS. Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to clinicaltrials.gov, 126 agents were in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is widely used in the life sciences and healthcare sectors, positively impacting market growth.

The market is still growing, with significant potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to diseases, and early detection is a crucial factor in avoiding disease or slowing its progression through early treatment.

Global Red Biotechnology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global red biotechnology market report based on product, end-use, and region:

• Product Outlook (Revenue, USD Billion, 2018 - 2030)
• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell-Based Immunotherapy Products
• Gene Therapy Products
• Cell Therapy Products
• Tissue-Engineered Products
• Stem Cells
• Cell Culture
• Viral Vector
• Enzymes
• Kits and Reagents
• Animal models
• Molecular diagnostics
• Others
• End-User Outlook (Revenue, USD Billion, 2018 - 2030)
• Academic Research Institutes
• CMOs & CROs
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Billion, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Red Biotechnology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Red Biotechnology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Red Biotechnology Market: Pipeline Analysis

Chapter 4. Red Biotechnology Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Red Biotechnology Market: Product Movement Analysis
• 4.3. Global Red Biotechnology Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Billion)
• 4.4. Monoclonal Antibodies
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Polyclonal Antibodies
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Recombinant Proteins
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Vaccines
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.8. Cell-Based Immunotherapy Products
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.9. Gene Therapy Products
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.10. Cell Therapy Products
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.11. Tissue - Engineered Products
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.12. Stem Cells
  • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.13. Cell Culture
  • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.14. Viral Vector
  • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.15. Enzymes
  • 4.15.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.16. Kits and Reagents
  • 4.16.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.17. Animal Models
  • 4.17.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.18. Molecular Diagnostics
  • 4.18.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.19. Others
  • 4.19.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Red Biotechnology Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. Red Biotechnology Market: End Use Movement Analysis
• 5.3. Global Red Biotechnology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
• 5.4. Academic Research Institutes
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. CMOs & CROs
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Pharmaceutical & Biotechnology Companies
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Red Biotechnology Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Red Biotechnology Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.6. Norway
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. Argentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Merck KGaA
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. F. Hoffmann-La Roche Ltd
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Pfizer Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Regeneron Pharmaceuticals, Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. AstraZeneca
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Takeda Pharmaceutical Company Limited
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Gilead Sciences, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Biogen
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Amgen Inc.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Celgene Corporation (acquired by Bristol-Myers Squibb Company)
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiativesa